VALN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Valneva SE (VALN) does not present a strong buy opportunity at the moment for a beginner investor with a long-term focus. The technical indicators are neutral, there are no significant trading trends, and the stock lacks immediate positive catalysts or proprietary trading signals. While the company has promising developments in its pipeline, such as the Lyme disease vaccine and Clostridioides difficile vaccine candidate, these are long-term projects with no immediate impact on the stock price. Given the investor's impatience and preference for long-term gains, it is better to hold off on investing in VALN at this time.
The MACD is negative and expanding, indicating bearish momentum. The RSI is neutral at 42.365, and moving averages are converging, showing no clear trend. Key support is at 10.385, and resistance is at 11.516. The stock has a 70% chance of gaining 0.13% in the next day, 2.34% in the next week, and 6.14% in the next month, but these are modest gains.
Additionally, Elaris FlexCo secured exclusive rights for a vaccine candidate technology, which could lead to long-term growth.
Overall sales decreased by 3.3% in 2024 due to planned reductions in third-party sales. Insiders and hedge funds are neutral, indicating no significant interest or confidence in the stock currently.
Valneva SE reported total revenue of €174.7 million for 2025, reflecting a 13.7% increase from 2024. However, product sales slightly decreased, and there is no detailed financial data available for deeper analysis.
No recent analyst rating or price target changes available for evaluation.
